Amarin Omega-3 Drug Lowers Blood-Fat Levels in Trial

An Amarin Corp. experimental medicine lowered fatty chemicals in the blood by as much as 45 percent in a final-stage clinical study. Amarin rose in pre- market trading.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.